ValiRx plc (VAL) AI Stock Analysis

• Market Cap: £1.97M
• Dividend Yield: N/A
• Average Volume (3M): 2.47M
• Price to Earnings (P/E): ―
• Beta (1Y): -0.13
• Revenue Growth: 418.49%
• EPS Growth: 27.86%
• Country: UK
• Employees: 16
• Sector: Healthcare
• Sector Strength: 52
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 374,348,660
• 10 Day Avg. Volume: 1,466,696
• 30 Day Avg. Volume: 2,467,733
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £0.50
• Price Target Upside: -3.85% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 46 Neutral
• Price Target: 0.50p ▼(-3.85% Downside)

ValiRx plc's overall stock score is primarily impacted by its challenging financial performance and unattractive valuation. However, recent corporate events and strategic partnerships provide a positive outlook, potentially enhancing future growth and industry positioning. Technical analysis indicates weak momentum, but oversold conditions may offer short-term opportunities.

ValiRx plc Business Overview & Revenue Model

Company Description

ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a small molecule that has completed Phase I/II trials for the treatment of prostate cancer and other hormone associated solid tumours comprising breast and ovarian cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of non-small cell lung cancer. Its drug candidates also comprise VAL301, a peptide ingredient that in pre-clinical development for the treatment of women with endometriosis; and BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19. ValiRx plc was incorporated in 2000 and is based in Hatfield, the United Kingdom.

How the Company Makes Money

ValiRx generates revenue primarily through the development and commercialization of its therapeutic products, which involves various stages of drug discovery, clinical trials, and regulatory approval. The company may also derive income from licensing agreements and partnerships with other pharmaceutical companies, which can include upfront payments, milestone payments, and royalties on sales of licensed products. Additionally, ValiRx may generate revenue through grants and funding from governmental and non-governmental organizations aimed at supporting biotech research and development. Factors contributing to its earnings include successful completion of clinical trials, achieving regulatory approvals, and establishing collaborations with larger pharmaceutical firms.

ValiRx plc Financial Statement Overview

Summary

ValiRx plc faces financial challenges with negative profitability and cash flow issues, typical of biotech firms in growth phases. Despite a solid equity position, profitability and cash flow constraints pose significant risks, necessitating improved operational efficiency and revenue generation.

Income Statement

ValiRx plc exhibits a challenging income statement with negative profitability margins. The gross profit margin is negative due to the cost of revenue exceeding total revenue, and the net profit margin is significantly negative, indicating substantial losses relative to revenue. Revenue growth is present, but the base is very low, which makes the growth percentage less impactful. EBIT and EBITDA margins are also negative, reflecting operational inefficiencies and high operating expenses.

Balance Sheet

The balance sheet shows a relatively solid equity position compared to liabilities, with a high equity ratio. However, the debt-to-equity ratio is low, indicating minimal leverage, which can be a double-edged sword in biotech if additional funding is needed. Return on equity is negative, driven by continuous net losses, signaling the need for improved profitability to enhance shareholder value.

Cash Flow

Cash flow statements reveal negative free cash flow, though there is a slight improvement in operating cash flow. The company relies heavily on financing activities for cash, which may not be sustainable long-term. The operating cash flow to net income ratio is negative, suggesting cash flow challenges in converting sales into cash. Free cash flow growth rates are negative, reflecting ongoing capital expenditure needs without sufficient revenue support.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	49.77K	9.60K	0.00	0.00	0.00
Gross Profit	-217.22K	-246.04K	-224.27K	-228.79K	-229.50K
EBITDA	-1.86M	-2.04M	-2.37M	-1.45M	-1.31M
Net Income	-1.92M	-2.04M	-2.41M	-1.55M	-1.47M
Balance Sheet
Total Assets	4.26M	3.13M	3.98M	3.52M	4.94M
Cash, Cash Equivalents and Short-Term Investments	1.56M	174.68K	1.14M	593.67K	1.85M
Total Debt	11.86K	22.07K	37.71K	58.72K	71.06K
Total Liabilities	346.41K	226.51K	149.65K	109.56K	182.40K
Stockholders Equity	4.32M	3.22M	4.05M	3.60M	4.91M
Cash Flow
Free Cash Flow	-1.62M	-2.08M	-1.71M	-1.26M	-2.00M
Operating Cash Flow	-1.58M	-1.77M	-1.71M	-1.26M	-1.91M
Investing Cash Flow	-38.16K	-306.18K	0.00	0.00	-91.29K
Financing Cash Flow	3.00M	1.12M	2.26M	7.34K	3.85M

ValiRx plc Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.52
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:VAL, the sentiment is Negative. The current price of 0.52 is below the 20-day moving average (MA) of 0.57, below the 50-day MA of 0.57, and below the 200-day MA of 0.73, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 31.53 is Neutral, neither overbought nor oversold. The STOCH value of 13.33 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:VAL.

ValiRx plc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.77B	-0.12	-39.07%	2.21%	22.68%	-1.42%
TCF	49 Neutral	£4.84M	―	-46.72%	―	-100.00%	68.42%
VAL	46 Neutral	£1.97M	―	-50.84%	―	418.49%	27.86%
OBD	46 Neutral	£9.30M	―	-333.59%	―	45.22%	55.71%
NFX	42 Neutral	£1.85M	―	-153.80%	―	―	-633.33%
CIZ	―	£6.14M	―	-272.62%	―	―	―
FAB	44 Neutral	£17.73M	―	-129.49%	―	14.12%	78.16%

ValiRx plc Corporate Events

ValiRx Secures Grant to Advance Cancer Research with Open University

ValiRx PLC, through its subsidiary Inaphaea BioLabs, has been awarded a Knowledge Transfer Voucher from The Open University to enhance its research capabilities in cancer therapeutics. This collaboration will focus on advanced imaging and machine learning techniques to improve drug response assessments in tumor models, aligning with recent regulatory changes that favor 3D cell cultures over animal testing. This initiative is expected to strengthen ValiRx’s technical capabilities and foster future collaborations, potentially accelerating the development of therapeutic candidates.

ValiRx Updates Evaluation Agreement with Stingray Bio for Cancer Therapeutics

ValiRx announced an update on its Evaluation Agreement with Stingray Bio, initially aimed at developing novel cancer therapeutics. The initial evaluation did not meet the criteria for licensing, leading to a new agreement focusing on in-silico and in-vitro optimization of Stingray’s drug compounds. ValiRx will fund the work, with an option to license the technology into a jointly owned Special Purpose Vehicle. This approach allows ValiRx to de-risk early-stage innovation and retain potential upside, while also enabling Stingray to seek additional funding, potentially accelerating the transition to clinical development.

ValiRx Enters Licensing Agreement with Dominion Biotech for PredictRx Platform

ValiRx Plc, through its subsidiary Inaphaea BioLabs, has entered into an exclusive licensing agreement with Dominion Biotech Ltd for its PredictRx® platform, a personalized cancer screening service. This agreement, which allows Inaphaea to receive a 50% share of global net revenues, is strategically significant for demonstrating the commercial application of ValiRx’s platform and establishing future buyout value, potentially enhancing the company’s industry positioning in precision oncology.

ValiRx Partners with VoxCell for Advanced Cancer Model Development

ValiRx PLC has announced a collaboration agreement with VoxCell BioInnovation to utilize ValiRx’s Patient Derived Cells in VoxCell’s 3D tissue culture models, focusing initially on Triple Negative Breast Cancer. This partnership aims to enhance the development of predictive, human-like tumor tissues for drug screening, leveraging ValiRx’s biobank and VoxCell’s advanced tissue models, and could potentially expand to other cancer indications, enhancing ValiRx’s industry positioning and offering significant implications for stakeholders involved in cancer therapeutics.

ValiRx PLC Announces Successful AGM Resolution Outcomes

ValiRx PLC, a company listed on the AIM Market of the London Stock Exchange, announced that all resolutions were passed at its recent Annual General Meeting. This development underscores the company’s strategic focus on advancing its pipeline of early-stage cancer therapeutics and women’s health products, potentially enhancing its market position and stakeholder confidence.

ValiRx Secures £16 Million Licensing Deal with Ambrose Healthcare for VAL401

ValiRx has announced that Ambrose Healthcare has exercised its option to license the VAL401 asset from ValiSeek Limited for £16 million plus royalties. This agreement marks a significant step for ValiRx, as it allows for the further development and commercialization of VAL401, a repurposed Risperidone asset with anticancer effects. The partnership with Ambrose, a specialist pharmaceutical company, aims to advance treatments for rare diseases, including pancreatic cancer, and underscores the strategic focus on innovative therapies. The collaboration is expected to enhance ValiRx’s industry positioning and provide potential therapeutic benefits across multiple cancer indications.

ValiRx Announces Post-Results Investor Webinar with CEO

ValiRx Plc announced a post-results webinar with CEO Mark Eccleston, scheduled for June 12, 2025, inviting existing and prospective investors to participate and submit questions. This initiative reflects ValiRx’s commitment to engaging with stakeholders and providing transparency about its operations, potentially enhancing investor confidence and market positioning.

ValiRx PLC Reports 2024 Financial Results and Strategic Restructuring

ValiRx PLC announced its audited results for the year ending December 31, 2024, highlighting operational and financial changes. The company secured grants for its Cytolytix and Inaphaea programs and initiated a strategic review to identify operational efficiencies, resulting in significant cost savings. Despite a comprehensive loss, the company’s cash balance improved significantly. The company also underwent a restructuring process to optimize efficiency, which included staff reductions and strategic shifts in its business model. These changes aim to enhance the company’s market positioning and operational effectiveness.

ValiRx and Omios Biologics Collaborate on Oncolytic Cancer Therapies

ValiRx plc, through its subsidiary Cytolytix Ltd., has entered into an Evaluation and Material Transfer Agreement with Omios Biologics to assess the potential of Cytolytix’s CLX001 oncolytic peptide technology in enhancing Omios’s next-generation oncolytic virus immunotherapies. This collaboration represents a strategic opportunity for ValiRx to expand its portfolio and commercialize innovative cancer therapeutics, potentially leading to a licensing agreement. The partnership aligns with Omios’s strategy to advance transformative cancer treatments, offering significant implications for both companies in the field of oncolytic immunotherapy.

ValiRx plc Announces Significant Shareholder Voting Rights Change

ValiRx plc has announced a change in its shareholder voting rights, with Jaspal Singh acquiring a significant stake, crossing the 8% threshold. This acquisition may influence the company’s strategic decisions and could impact its market positioning, as stakeholders observe the potential implications for future governance and operational directions.

ValiRx Extends Drug Repurposing Deal with Dominion Biotech

ValiRx’s subsidiary, Inaphaea BioLabs, has extended its agreement with Dominion Biotech to explore repurposing FDA-approved drugs for cancer applications. This collaboration aims to unlock potential new cancer treatments by analyzing existing data sets, potentially accelerating development timelines and offering new options for patients. Both companies will share costs and revenues from any resulting patents and commercialized assets, enhancing ValiRx’s operational impact and industry positioning.